Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice

Chiara Azzari, Federico Martinón-Torres, Heinz Josef Schmitt, Ron Dagan

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Since the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), PCVs with extended coverage have become available, and there is emerging global evidence that these vaccines, in particular PCV13, have further reduced rates of invasive pneumococcal disease compared with PCV7. The present article aims to address emerging topics related to PCV13 use in routine clinical practice; specifically: (1) the potential role of high-valent PCVs in reducing pneumococcal disease burden; (2) the impact of PCVs on nasopharyngeal carriage and how this may contribute to reductions in otitis media and pneumonia, as well as the prevalence of resistant pneumococcal strains; (3) new PCV13 indications and (4) importance of schedule adherence for PCV in the prevention of cases of vaccine serotype-specific invasive pneumococcal disease. The beneficial effects of PCVs in protecting individuals from a wide spectrum of pneumococcal diseases can be increased by improving the vaccine coverage and adhering to the recommended vaccination schedules. There is increasing evidence that PCV13 has reduced much of the post-PCV7 burden of pneumococcal diseases in the pediatric community, including reducing pneumococcal colonization and the incidence of invasive pneumococcal disease and mucosal diseases. This has also led to a reduction in antibiotic- resistant pneumococcal diseases. The role of PCV13 in clinical practice is evolving, with PCV13 now available for children and adolescents between the ages of 6 weeks and 17 years, thus ensuring that children in all age groups can be protected against vaccine-serotype pneumococcal diseases. Continued surveillance is warranted to monitor the impact of PCV13 on disease burden.

Original languageEnglish
Pages (from-to)858-864
Number of pages7
JournalPediatric Infectious Disease Journal
Volume33
Issue number8
DOIs
StatePublished - 1 Jan 2014

Keywords

  • Invasive pneumococcal diseases
  • PCV13
  • Pneumococcal conjugate vaccine
  • Pneumococcal diseases

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice'. Together they form a unique fingerprint.

Cite this